Nautilus Biotechnology (NAUT) Depreciation and Depletion (2020 - 2026)
Nautilus Biotechnology's (NAUT) quarterly Depreciation and Depletion came in at $334000.0 in Q1 2026, down 28.17% year-on-year from $465000.0 in Q1 2025, and down 16.5% quarter-over-quarter from $400000.0 in Q4 2025.
Nautilus Biotechnology (NAUT) Depreciation and Depletion (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has disclosed Depreciation and Depletion across 7 years of filings, most recently posting $334000.0 for Q1 2026.
- Depreciation and Depletion for Q1 2026 came in at $334000.0, down 28.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (down 21.93% YoY), and the FY2025 annual result was $1.7 million, down 15.0% from the prior year.
- Depreciation and Depletion came in at $334000.0 for Q1 2026 at Nautilus Biotechnology, down from $400000.0 in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $549000.0 in Q4 2023 to a low of $300000.0 in Q1 2022.
- The 5-year median for Depreciation and Depletion is $400000.0 (2023), against an average of $413705.9.
- Across the five-year window, Depreciation and Depletion surged 83.0% in 2023 and dropped 28.17% in 2026, its largest moves.
- Nautilus Biotechnology's Depreciation and Depletion stood at $300000.0 in 2022, then soared by 83.0% to $549000.0 in 2023, then dropped by 8.93% to $500000.0 in 2024, then retreated by 20.0% to $400000.0 in 2025, then slipped by 16.5% to $334000.0 in 2026.
- The last three Depreciation and Depletion figures came in at $334000.0 (Q1 2026), $400000.0 (Q4 2025), and $400000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Nautilus Biotechnology | 289.99 Mn | 194.12 Mn | - | 334,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 334,000.00 |
| Mar 31, 2026 | 334,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 465,000.00 |
| Mar 31, 2025 | 465,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Dec 31, 2023 | 549,000.00 |
| Dec 31, 2023 | 549,000.00 |